Results 241 to 250 of about 36,256 (261)

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Nature Medicine, 2021
Thomas Filleron, Florence Coussy, Benoit You   +2 more
exaly  

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Nature Medicine, 2021
Thomas Powles, Joan Carles Galcerán, Daniel P Petrylak   +2 more
exaly  

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Nature Medicine, 2021
Patrick Forde, Valsamo Anagnostou, Suzanne E Dahlberg   +2 more
exaly  

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

Nature Medicine, 2023
Marion Thibaudin, Romain Boidot, Francois Ghiringhelli   +2 more
exaly  

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Lancet Oncology, The, 2021
Katsuyuki Hotta, Oleksandr Voitko, Igor N Bondarenko   +2 more
exaly  

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Taofeek Kunle Owonikoko, Nabil F Saba   +2 more
exaly  

Biomarkers for immunotherapy of hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2023
Tim F Greten, Augusto Villanueva, Benjamin Ruf   +2 more
exaly  

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Journal of Clinical Oncology, 2022
David Spigel, Corinne Faivre-Finn, David Planchard   +2 more
exaly  

A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

Nature Cancer, 2022
Laurel B Darragh, Michael W Knitz, Thomas E Bickett   +2 more
exaly  

Durvalumab

Reactions Weekly, 2017
openaire   +1 more source